# Kyverna Therapeutics

> Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company in Emeryville, California, developing engineered T cell therapies for autoimmune disease. Kyverna adapts CD19 CAR T-cell therapy — originally developed for B cell cancers — to deeply deplete the B cells that drive autoimmunity, with the goal of durable, drug-free remission.

Kyverna is a biopharmaceutical operating company. It publishes **no public developer API, SDK, developer portal, or machine-readable API specification**. There is no GitHub organization, no `/.well-known/` surface, and no `/llms.txt` on the corporate host. This file is generated by the API Evangelist enrichment pipeline from the company's public web surface so agents can answer questions about Kyverna without inventing a developer program that does not exist.

- Generated: 2026-07-19
- Method: generated (from apis.yml + public site enumeration)
- Source: https://kyvernatx.com/

## Company

- [Kyverna Therapeutics](https://kyvernatx.com/): Corporate home page.
- [Inside Kyverna](https://kyvernatx.com/inside-kyverna/): Company, culture, and mission overview.
- [Leadership](https://kyvernatx.com/leadership/): Executive and scientific leadership team.
- [Mission and Values](https://kyvernatx.com/mission-values/): Stated company mission and values.
- [Contact](https://kyvernatx.com/contact/): Headquarters at 5980 Horton St, STE 200, Emeryville, CA 94608; general hello@kyvernatx.com, media@kyvernatx.com, partners@kyvernatx.com, InvestorRelations@kyvernatx.com.
- [Careers](https://kyvernatx.com/careers/): Open roles.

## Science and pipeline

- [Platform and Pipeline](https://kyvernatx.com/platform-pipeline/): Overview of the CAR T platform and development programs.
- [Pipeline](https://kyvernatx.com/platform-pipeline/pipeline/): Program-by-program development stage.
- [CAR T Cell Therapy](https://kyvernatx.com/platform-pipeline/car-t-cell-therapy/): How CD19 CAR T-cell therapy is applied to autoimmune disease.
- [Clinical Trials](https://kyvernatx.com/platform-pipeline/clinical-trials/): Active and planned clinical studies.
- [The Opportunity](https://kyvernatx.com/platform-pipeline/opportunity/): Market and unmet-need framing.

Lead candidate: mivocabtagene autoleucel (miv-cel, KYV-101), a fully human CD19 CAR T-cell therapy. Phase 2 programs in stiff person syndrome, myasthenia gravis, and multiple sclerosis; Phase 1/2 programs in systemic sclerosis and in lupus nephritis (United States and Germany). Next-generation autologous and allogeneic constructs, including KYV-201, are built on the Ingenui-T rapid manufacturing platform.

## Patients

- [Patients](https://kyvernatx.com/patients/): Patient-facing hub.
- [Lupus Nephritis](https://kyvernatx.com/patients/lupus-nephritis/)
- [Multiple Sclerosis](https://kyvernatx.com/patients/multiple-sclerosis/)
- [Myasthenia Gravis](https://kyvernatx.com/patients/myasthenia-gravis/)
- [Stiff Person Syndrome](https://kyvernatx.com/patients/stiff-person-syndrome/)
- [Systemic Sclerosis](https://kyvernatx.com/patients/systemic-sclerosis/)
- [Patient Experience](https://kyvernatx.com/patients/experience/): What the treatment journey involves.
- [Success Stories](https://kyvernatx.com/patients/success-stories/)

## Knowledge center

- [Knowledge Center](https://kyvernatx.com/knowledge-center/): Scientific resource hub.
- [Publications](https://kyvernatx.com/knowledge-center/publications/): Congress posters and presentations (ACR, AAN, ECTRIMS, EULAR, AANEM, MGFA, DGN, TANDEM, ISCT).
- [Educational Videos](https://kyvernatx.com/knowledge-center/educational-videos/)
- [Symposium](https://kyvernatx.com/knowledge-center/symposium/)

## Investors and news

- [Investor Relations](https://ir.kyvernatx.com/): Nasdaq: KYTX investor site.
- [News Releases](https://ir.kyvernatx.com/news-releases): Dated corporate and clinical press releases.

## Legal

- [Privacy Policy (US)](https://kyvernatx.com/privacy-policy/)
- [Privacy Policy (EU/UK)](https://kyvernatx.com/privacy-policy-eu-uk/)

No terms of service / terms of use page is published on the corporate host.

## Social

- [LinkedIn](https://www.linkedin.com/company/kyverna/)
- [X](https://x.com/Kyverna_Tx/)

## Optional

- [Domain security posture](security/kyverna-therapeutics-domain-security.yml): Probed TLS/DNS posture — TLS 1.3, SPF and DMARC (p=reject) present; no HSTS, no DNSSEC, no CAA.
- [Well-known probe record](well-known/kyverna-therapeutics-well-known.yml): All standard `/.well-known/` paths return 404.